These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9815197)

  • 1. Effects of camptothecin analogues on DNA transformations mediated by calf thymus and human DNA topoisomerases I.
    Wang X; Short GF; Kingsbury WD; Johnson RK; Hecht SM
    Chem Res Toxicol; 1998 Nov; 11(11):1352-60. PubMed ID: 9815197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification.
    Wang X; Wang LK; Kingsbury WD; Johnson RK; Hecht SM
    Biochemistry; 1998 Jun; 37(26):9399-408. PubMed ID: 9649322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of topoisomerase I function by coralyne and 5,6-dihydrocoralyne.
    Wang LK; Rogers BD; Hecht SM
    Chem Res Toxicol; 1996; 9(1):75-83. PubMed ID: 8924619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
    J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA topoisomerase I-mediated formation of structurally modified DNA duplexes. Effects of metal ions and topoisomerase I inhibitors.
    Wang X; Henningfeld KA; Hecht SM
    Biochemistry; 1998 Feb; 37(8):2691-700. PubMed ID: 9485420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of camptothecin resistance by human topoisomerase I mutations.
    Chrencik JE; Staker BL; Burgin AB; Pourquier P; Pommier Y; Stewart L; Redinbo MR
    J Mol Biol; 2004 Jun; 339(4):773-84. PubMed ID: 15165849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of camptothecin derivatives by conjugation to triple helix-forming oligonucleotides.
    Arimondo PB; Laco GS; Thomas CJ; Halby L; Pez D; Schmitt P; Boutorine A; Garestier T; Pommier Y; Hecht SM; Sun JS; Bailly C
    Biochemistry; 2005 Mar; 44(11):4171-80. PubMed ID: 15766244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of camptothecin on the DNA-relaxing and DNA-cleavage activity of calf thymus topoisomerase I].
    Bronshteĭn IB; Gromova II; Bukhman VL; Kafiani KA
    Mol Biol (Mosk); 1989; 23(2):491-501. PubMed ID: 2549395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of camptothecin analog-topoisomerase I-DNA ternary complexes: a molecular dynamics study.
    Siu FM; Che CM
    J Am Chem Soc; 2008 Dec; 130(52):17928-37. PubMed ID: 19035632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of 10,11-methylenedioxy-14-azacamptothecin.
    Elban MA; Sun W; Eisenhauer BM; Gao R; Hecht SM
    Org Lett; 2006 Aug; 8(16):3513-6. PubMed ID: 16869648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex.
    Wang X; Zhou X; Hecht SM
    Biochemistry; 1999 Apr; 38(14):4374-81. PubMed ID: 10194356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment.
    Xiao X; Cushman M
    J Org Chem; 2005 Nov; 70(23):9584-7. PubMed ID: 16268636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
    Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
    Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 14-azacamptothecin: a potent water-soluble topoisomerase I poison.
    Cheng K; Rahier NJ; Eisenhauer BM; Gao R; Thomas SJ; Hecht SM
    J Am Chem Soc; 2005 Jan; 127(3):838-9. PubMed ID: 15656613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
    Streltsov SA
    J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dumbbell-shaped circular oligonucleotides as inhibitors of human topoisomerase I.
    Li X; Tao Ng MT; Wang Y; Liu X; Li T
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4967-71. PubMed ID: 17591440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibitors of DNA topoisomerases].
    Andoh T
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and properties of camptothecin derivatives, their protonated forms, and model interaction with the topoisomerase I-DNA complex.
    Ivanova B; Spiteller M
    Biopolymers; 2012 Feb; 97(2):134-44. PubMed ID: 21898362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luotonin A. A naturally occurring human DNA topoisomerase I poison.
    Cagir A; Jones SH; Gao R; Eisenhauer BM; Hecht SM
    J Am Chem Soc; 2003 Nov; 125(45):13628-9. PubMed ID: 14599178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the role of E-ring oxygen atoms in the binding of camptothecin to the topoisomerase I-DNA covalent binary complex.
    Rahier NJ; Eisenhauer BM; Gao R; Thomas SJ; Hecht SM
    Bioorg Med Chem; 2005 Feb; 13(4):1381-6. PubMed ID: 15670945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.